Response to letter re: Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers

Jean Yves Blay; M. Brahmi; A. Dufresne; Pierre-Étienne Heudel

doi:10.1016/j.esmoop.2025.104531

Abstract

1 min read

In response to the letter from Nishida and Shimada1 regarding our article published in ESMO Open titled ‘Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers’, we would like to thank the authors for their insightful comments and their interest in our work.2

Related publications

Article2025

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers

Jean Yves Blay, M. Brahmi, Armelle Dufresne, A. Swalduz, Virginie Avrillon, Souad Assaad, C. Decroisette, Bénédicte Mastroïanni, Margaux Dupont, F Bourbotte-Salmon, I. Ray-Coquard, Pierre Méeus, Aurélie Dutour, Marie Castets, M. Pérol, Pierre-Étienne Heudel

Letter2020

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma

Lauriane Eberst, Philippe A. Cassier, Mehdi Brahmi, Franck Tirode, Jean Yves Blay

Letter2018

Reply to the letter to the editor ‘Body mass index and 20-specific cancers—re-analyses of dose–response meta-analyses of observational studies’ by Markozannes et al.

Eun Kyoung Choi, Michael Eisenhut, Kee Hag Lee, Jae Il Shin

Letter2022

Re: Reply to letter to the editor re: ‘practical guide on the use of imiquimod cream to treat lentigo maligna’

Pascale Guitera, Andréanne Waddell, Elizabeth Paton, Gerald B. Fogarty, Angela Hong, Richard A Scolyer, Jonathan R. Stretch, Brett O’Donnell, Giovanni Pellacani

Article2017

Abstract IA10: Drugging the ribosome at the level of synthesis and translation to treat solid and hematologic cancers

Ross D. Hannan, Nadine Hein, Katherine M. Hannan, Gretchen Poortinga, Elaine Sanij, Jirawas Sornkom, Kylee Maclachlan, Andrew Cuddihy, Carleen Cullinane, Luc Furic, Denis Drygin, Mustapha Haddach, Simon J. Harrison, Grant A. McArthur, Richard B. Pearson